ArticleClinical and translational medicine2021

BCL2L2 loss renders -14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors.

Yinfeng Lyu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.